zellweger-spectrum-disorders

Zellweger Spectrum Disorders

Introduction

Zellweger Spectrum Disorders is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Zellweger spectrum disorders (ZSD) are a group of rare, autosomal recessive peroxisome biogenesis disorders caused by biallelic mutations in any one of 13 PEX genes that encode peroxin proteins required for peroxisome assembly and function . The disorders represent a clinical continuum ranging from the most severe form, Zellweger syndrome (ZS), through intermediate neonatal adrenoleukodystrophy (NALD), to the mildest form, infantile Refsum disease (IRD) . Loss of functional peroxisomes disrupts multiple metabolic pathways — including very long-chain fatty acid (VLCFA) beta-oxidation, plasmalogen synthesis, and bile acid metabolism — leading to severe multisystem disease with prominent neurodegeneration, hepatic dysfunction, and craniofacial dysmorphism . [@refa]

Overview

Zellweger spectrum disorders are estimated to occur in approximately 1 in 50,000 individuals worldwide, with higher incidence reported in certain populations, including the Saguenay-Lac-Saint-Jean region of Quebec (approximately 1 in 12,000) . The disorders affect males and females equally. [@zellweger]

...

Zellweger Spectrum Disorders

Introduction

Zellweger Spectrum Disorders is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Zellweger spectrum disorders (ZSD) are a group of rare, autosomal recessive peroxisome biogenesis disorders caused by biallelic mutations in any one of 13 PEX genes that encode peroxin proteins required for peroxisome assembly and function . The disorders represent a clinical continuum ranging from the most severe form, Zellweger syndrome (ZS), through intermediate neonatal adrenoleukodystrophy (NALD), to the mildest form, infantile Refsum disease (IRD) . Loss of functional peroxisomes disrupts multiple metabolic pathways — including very long-chain fatty acid (VLCFA) beta-oxidation, plasmalogen synthesis, and bile acid metabolism — leading to severe multisystem disease with prominent neurodegeneration, hepatic dysfunction, and craniofacial dysmorphism . [@refa]

Overview

Zellweger spectrum disorders are estimated to occur in approximately 1 in 50,000 individuals worldwide, with higher incidence reported in certain populations, including the Saguenay-Lac-Saint-Jean region of Quebec (approximately 1 in 12,000) . The disorders affect males and females equally. [@zellweger]

The syndrome was first described by Hans Zellweger and colleagues in 1964 as a familial syndrome of multiple congenital defects including hepatomegaly, polycystic kidneys, and cerebral abnormalities . The underlying biochemical defect — absence of functional peroxisomes — was identified in 1973, making ZS the first recognized peroxisome biogenesis disorder. The molecular basis was progressively elucidated through the 1990s and 2000s with identification of the PEX genes. [@zellwegera]

Genetics and Molecular Biology

PEX Genes and Peroxin Proteins

Peroxisome biogenesis requires the coordinated action of at least 16 peroxin proteins (PEX proteins). Mutations in 13 PEX genes have been identified as causes of ZSD : [@pex2005]

| Gene | Chromosome | Frequency | Function | [@peroxisome2016]
|------|-----------|-----------|----------| [@zellweger2015]
| PEX1 | 7q21.2 | ~65% of ZSD cases | AAA ATPase; peroxisomal matrix protein import | [@cerebrohepatorenal1986]
| PEX6 | 6p21.1 | ~10-16% | AAA ATPase; partners with PEX1 | [@cerebral2008]
| PEX10 | 1p36.32 | ~3-5% | RING finger E3 ligase; matrix protein import | [@zellwegerb]
| PEX12 | 17q12 | ~5% | RING finger E3 ligase; ubiquitination | [@modelling2025]
| PEX26 | 22q11.21 | ~3-5% | PEX1/PEX6 docking factor | [@estimation2025]
| PEX2 | 8q21.13 | ~3% | RING finger E3 ligase |
| PEX13 | 2p15 | ~2% | Peroxisomal membrane protein; docking complex |
| PEX5 | 12p13.31 | Rare | PTS1 receptor; matrix protein import |
| PEX3 | 6q24.2 | Rare | Membrane biogenesis |
| PEX7 | 6q23.3 | Rare | PTS2 receptor |
| PEX14 | 1p36.22 | Rare | Docking complex; matrix protein import |
| PEX16 | 11p11.2 | Rare | Membrane biogenesis |
| PEX19 | 1q22 | Rare | Membrane protein import |

The most common mutation is the PEX1 c.2528G>A (p.G843D) missense variant, a temperature-sensitive allele that retains partial peroxisomal function and is typically associated with milder phenotypes .

Peroxisomal Metabolic Functions

Peroxisomes perform critical metabolic functions that are disrupted in ZSD :

Beta-oxidation of VLCFAs: Peroxisomes are the exclusive site of VLCFA (≥C22) beta-oxidation; deficiency leads to toxic VLCFA accumulation

Plasmalogen biosynthesis: First two steps of ether phospholipid (plasmalogen) synthesis occur in peroxisomes; deficiency impairs myelin formation

Bile acid synthesis: Peroxisomal enzymes catalyze the final steps of bile acid synthesis from cholesterol; deficiency leads to accumulation of toxic bile acid intermediates (DHCA and THCA)

Phytanic acid alpha-oxidation: Peroxisomes degrade dietary phytanic acid; accumulation causes neurological and retinal damage

Pipecolic acid metabolism: L-pipecolic acid oxidase resides in peroxisomes; deficiency leads to hyperpipecolic acidemia

Glyoxylate metabolism: Deficiency contributes to oxalate accumulation and renal dysfunction

[oxidative-stress](/mechanisms/oxidative-stress) metabolism: Peroxisomes contain catalase and other antioxidant enzymes

Pathophysiology

Neurodegeneration Mechanisms

The neurological devastation in ZSD arises from multiple interacting pathogenic mechanisms :

Neuronal Migration Defects

Impaired peroxisomal function during brain development disrupts neuronal migration, producing characteristic cortical malformations :

• Pachygyria: Thickened gyri with simplified cortical folding, predominantly in medial/perirolandic regions
• Polymicrogyria: Excessive small, disorganized gyri in lateral/perisylvian [cortex](/brain-regions/cortex)
• Heterotopias: Ectopic clusters of [neurons](/entities/neurons) that failed to reach their cortical targets
• These defects reflect the requirement for peroxisomal lipid metabolism in the signaling pathways that guide migrating [neurons](/entities/neurons)

Demyelination and Leukodystrophy

Plasmalogen deficiency severely impairs myelin formation and maintenance :

• Plasmalogens constitute up to 80% of myelin phospholipids
• Deficiency leads to progressive demyelination (leukodystrophy)
• [oligodendrocytes](/entities/oligodendrocytes) are particularly vulnerable to VLCFA toxicity and plasmalogen depletion

VLCFA Toxicity

Accumulation of VLCFAs in neural membranes disrupts membrane fluidity, alters ion channel function, and triggers inflammatory cascades .

Oxidative Stress

Loss of peroxisomal antioxidant enzymes (catalase, superoxide dismutase) leads to accumulation of [oxidative-stress](/mechanisms/oxidative-stress) and oxidative damage to [neurons](/entities/neurons) and glia .

Mitochondrial Dysfunction

Peroxisomal and mitochondrial metabolism are intimately linked; peroxisomal loss causes secondary mitochondrial dysfunction, further compromising neuronal energy metabolism .

Hepatic Pathology

Liver dysfunction results from bile acid synthesis defects, VLCFA accumulation, and oxidative damage :

• Hepatomegaly with micronodular cirrhosis
• Intrahepatic cholestasis
• Progressive liver failure in severe cases

Adrenal Pathology

Adrenal insufficiency can develop due to VLCFA accumulation in adrenal cortical cells, similar to the pathology seen in [adrenoleukodystrophy](/diseases/adrenoleukodystrophy) .

Clinical Features

Zellweger Syndrome (Most Severe)

Classic Zellweger syndrome presents in the neonatal period with a characteristic constellation of features :

Craniofacial dysmorphism:

• High forehead with large, widely open anterior fontanelle
• Flat supraorbital ridges
• Broad nasal bridge with anteverted nares
• Micrognathia (small jaw)
• Shallow orbital ridges
• Epicanthal folds
• High-arched palate

Neurological features:

• Profound hypotonia ("floppy infant")
• Absent or severely diminished deep tendon reflexes
• Seizures (often neonatal onset)
• Absent psychomotor development
• Sensorineural hearing loss
• Optic nerve hypoplasia or atrophy
• Retinal dystrophy (retinitis pigmentosa)

Systemic features:

• Hepatomegaly with liver dysfunction
• Renal cortical cysts
• Chondrodysplasia punctata (stippled calcification of epiphyses, particularly patellae)
• Feeding difficulties and failure to thrive
• Adrenal insufficiency

Most infants with classic ZS do not survive beyond the first year of life .

Neonatal Adrenoleukodystrophy (Intermediate)

Patients with intermediate-severity ZSD present with :

• Neonatal hypotonia (less severe than ZS)
• Mild craniofacial dysmorphism
• Developmental delay with some milestone acquisition
• Progressive leukodystrophy in infancy/childhood
• Seizures (often developing after the neonatal period)
• Progressive sensorineural hearing loss
• Retinal dystrophy
• Hepatic dysfunction
• Survival into childhood (typically to mid-childhood)

Infantile Refsum Disease (Mildest)

The mildest form presents with :

• Mild developmental delay
• Sensorineural hearing loss (often presenting feature)
• Retinitis pigmentosa with progressive visual loss
• Hepatic dysfunction (variable severity)
• Mild craniofacial features
• Cognitive impairment (variable; some patients have near-normal intelligence)
• Peripheral neuropathy
• Survival into adulthood in some cases, though with progressive disability

Diagnosis

Biochemical Testing

The primary diagnostic step involves detection of characteristic metabolic abnormalities :

• Plasma VLCFAs: Elevated C26:0, C26:1, and elevated C26:0/C22:0 and C24:0/C22:0 ratios (most sensitive screening test)
• Plasma phytanic acid: Elevated
• Plasma pristanic acid: Elevated
• Plasma pipecolic acid: Elevated
• Plasma bile acids: Elevated DHCA and THCA (C27 bile acid intermediates)
• Red blood cell plasmalogens: Reduced
• Urine organic acids: Elevated dicarboxylic acids

Neuroimaging

Brain MRI reveals characteristic findings that correlate with disease severity :

Zellweger Syndrome:

• Cerebral cortical malformations: pachygyria-polymicrogyria (centrosylvian distribution)
• Germinolytic cysts (subependymal cysts, especially at the caudothalamic groove)
• Severe white matter signal abnormalities (leukodystrophy)
• Delayed myelination
• Cerebellar atrophy

Intermediate/Mild ZSD:

• Progressive white matter disease (leukodystrophy)
• Cerebellar atrophy
• Corpus callosum abnormalities
• Absence of cortical malformations (distinguishing from classic ZS)

Genetic Testing

Identification of biallelic pathogenic variants in one of the 13 PEX genes confirms the diagnosis . Next-generation sequencing (gene panels or whole exome sequencing) is now the preferred confirmatory approach.

Newborn Screening

Elevated C26:0-lysophosphatidylcholine (C26:0-LPC) on dried blood spot by tandem mass spectrometry can identify ZSD in newborn screening programs, and ZSD has been added to the Recommended Uniform Screening Panel (RUSP) in the United States .

Neuropathology

Macroscopic Findings

The brain shows :

• Abnormal gyral pattern with pachygyria and polymicrogyria
• Reduced white matter volume
• Cerebellar atrophy (particularly in milder forms with longer survival)
• Subependymal germinolytic cysts

Microscopic Findings

• Cortical dysplasia: Disorganized cortical lamination with heterotopic [neurons](/entities/neurons) in the white matter and leptomeninges
• Demyelination: Widespread loss of myelin with [oligodendrocytes](/entities/oligodendrocytes) depletion
• Lipid-laden macrophages: Sudanophilic leukodystrophy
• Neuronal lipid storage: PAS-positive lipid inclusions in [neurons](/entities/neurons)
• Perivascular inflammation: Inflammatory cell infiltrates around blood vessels, particularly in the demyelinating white matter
• Absent peroxisomes: Electron microscopy demonstrates absence of morphologically recognizable peroxisomes in hepatocytes and other cell types

Treatment and Management

Current Standard of Care

There is no curative treatment for ZSD. Management is supportive and multidisciplinary :

Nutritional management:

• Dietary restriction of phytanic acid (limiting dairy fat and ruminant fats)
• DHA (docosahexaenoic acid) supplementation to address documented deficiency
• Fat-soluble vitamin supplementation (A, D, E, K)
• Gastrostomy tube placement for patients with severe dysphagia

Neurological management:

• Antiepileptic medications for seizure control
• Physical and occupational therapy
• Hearing aids or cochlear implants for sensorineural hearing loss

Hepatic management:

• Ursodeoxycholic acid for cholestasis
• Monitoring for liver failure

Endocrine management:

• Cortisol replacement for adrenal insufficiency

Ophthalmological management:

• Regular retinal examinations
• Correction of refractive errors

Emerging Therapies

Cholic Acid (Cholbam)

Cholic acid was approved by the FDA for bile acid synthesis defects, including those in ZSD :

• Provides primary bile acid to compensate for deficient peroxisomal bile acid synthesis
• Reduces toxic bile acid intermediate (DHCA, THCA) levels
• Improves liver function in some patients
• Does not address the underlying neurological disease

Gene Therapy

[gene-therapy](/therapeutics/gene-therapy) approaches for ZSD are in preclinical development :

• AAV-based gene replacement targeting the most commonly mutated PEX genes (particularly PEX1)
• Challenges include the multisystem nature of the disease and the large size of some PEX genes
• Zebrafish and mouse models are being used to develop and test therapeutic strategies

Pharmacological Chaperones

For the common PEX1-G843D missense mutation, pharmacological chaperone strategies that stabilize the misfolded protein and restore partial peroxisomal function are under investigation .

Relationship to Other Diseases

ZSD shares pathogenic mechanisms and clinical overlap with several other conditions:

• [adrenoleukodystrophy](/diseases/adrenoleukodystrophy): X-linked peroxisomal disorder affecting VLCFA beta-oxidation (ABCD1 transporter); shares VLCFA accumulation and demyelination pathology
• [pelizaeus-merzbacher-disease](/diseases/pelizaeus-merzbacher-disease): Another inherited leukodystrophy with myelin deficiency
• [krabbe-disease](/diseases/krabbe-disease) and [metachromatic-leukodystrophy](/diseases/metachromatic-leukodystrophy): Leukodystrophies with demyelination
• [canavan-disease](/diseases/canavan-disease): Another dysmyelinating leukodystrophy
• [alexander-disease](/diseases/alexander-disease): Leukodystrophy due to [glial-fibrillary-acidic-protein](/entities/glial-fibrillary-acidic-protein) mutations
• Refsum disease (classic/adult): Peroxisomal single-enzyme defect (phytanoyl-CoA hydroxylase) with phytanic acid accumulation
• Rhizomelic chondrodysplasia punctata (RCDP): Related peroxisome biogenesis disorder with plasmalogen deficiency

See Also

• [adrenoleukodystrophy](/diseases/adrenoleukodystrophy) — X-linked peroxisomal VLCFA disorder
• [krabbe-disease](/diseases/krabbe-disease) — lysosomal leukodystrophy
• [metachromatic-leukodystrophy](/diseases/metachromatic-leukodystrophy) — lysosomal leukodystrophy
• [pelizaeus-merzbacher-disease](/diseases/pelizaeus-merzbacher-disease) — dysmyelinating leukodystrophy
• [canavan-disease](/diseases/canavan-disease) — spongiform leukodystrophy
• [oxidative-stress](/mechanisms/oxidative-stress) — consequence of peroxisomal loss
• [gene-therapy](/therapeutics/gene-therapy) — emerging therapeutic approach

External Links

• [Zellweger Spectrum Disorder - GeneReviews](https://www.ncbi.nlm.nih.gov/books/NBK1448/)
• [Zellweger Spectrum Disorder - OMIM #214100](https://omim.org/entry/214100)
• [Zellweger Syndrome - Orphanet](https://www.orpha.net/en/disease/detail/912)
• [ZSD - NORD](https://rarediseases.org/rare-diseases/zellweger-spectrum-disorders/)
• [ZSD - MedlinePlus](https://medlineplus.gov/genetics/condition/zellweger-spectrum-disorder/)
• [Global Foundation for Peroxisomal Disorders](https://thegfpd.org/)

Background

The study of Zellweger Spectrum Disorders has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

Recent advances in Zellweger Spectrum Disorders have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:

• Genetic studies: Identification of new genetic risk factors and mechanistic insights
• Biomarker research: Development of diagnostic and prognostic biomarkers
• Therapeutic approaches: Investigation of novel treatment strategies
• Clinical trials: Ongoing Phase I-III trials for new therapies

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References

Unknown, (n.d.)

Unknown, (n.d.)

Unknown, [Zellweger Spectrum Disorders. National Organization for Rare Disorders (NORD] (n.d.)

Unknown, Zellweger Spectrum Disorder. MedlinePlus Genetics. [Link) (n.d.)

[Unknown, PEX1 mutations in the Zellweger spectrum of the peroxisome biogenesis disorders. American Journal of Medical Genetics Part A. 2005;136(3):243-248. [Link) (2005)](https://pubmed.ncbi.nlm.nih.gov/16086329/)

Unknown, Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines. Molecular Genetics and Metabolism. 2016;117(3):313-321. [Link) (2016)

Unknown, Zellweger spectrum disorders: clinical overview and management approach. Orphanet Journal of Rare Diseases. 2015;10:151. [Link) (2015)

Unknown, Cerebro-hepato-renal syndrome of Zellweger: an inherited disorder of neuronal migration. Acta Neuropathologica. 1986;69:292-298. [Link) (1986)

Unknown, [Cerebral MRI as a valuable diagnostic tool in Zellweger spectrum patients. Journal of Inherited Metabolic Disease. 2008;31(Suppl 2]:S270-S280 (2008)

Unknown, Zellweger Spectrum Disorder - Newborn Screening. HRSA. [Link) (n.d.)

Unknown, Modelling Peroxisomal Disorders in Zebrafish. Cells. 2025;14(2):147. [Link) (2025)

Unknown, Estimation of PEX1-mediated Zellweger spectrum disorder births and population prevalence by population genetics modeling. Genetics in Medicine Open. 2025. [Link) (2025)